China Pregabalin Market Investigation Report, 2015-2020 & 2020-2024 –

12-Oct-2020 Intellasia | BusinessWire | 10:30 PM Print This Post

DUBLIN--(BUSINESS WIRE)--The "Investigation Report on the Chinese Pregabalin Market, 2020-2024 " report has been added to's offering.

There is a continuous rise in the number of people suffering from indications for Pregabalin. For example, the number of epileptics in China has exceeded 10 million and increases by 500 thousand every year. Therefore, Pregabalin has bright prospects in China.

Pregabalin is a new-generation drug for neuralgia treatment. In July 2004, it was approved by the European Union to treat some epileptic seizures in adults. In December 2004, it was approved by the U.S. Food and Drug Administration (FDA) to treat diabetic peripheral neuralgia and postherpetic neuralgia. In 2006, generalized anxiety disorder and social anxiety disorder became new indications of Pregabalin. In 2007, Pregabalin was approved by the FDA as the first drug to treat fibromyalgia syndrome. In 2012, Pregabalin was approved by the FDA to treat spinal cord injury (SCI)-related pains. In 2010, Lyrica was approved to enter China.

According to this research, the sales value of Lyrica increased by more than 700 times from about CNY 200,000 in 2010 to over 142.6 million in 2019. Due to Lyrica's success, many domestic manufacturers applied for Pregabalin production. Chongqing Succeway Pharmaceutical Co., Ltd.'s Pregabalin (trade name: Lairuike) was put in the market after obtaining the production license in 2013 and is gradually taking market share from Pfizer.

By sales value, in 2019, Pfizer's Lyrica had a market share of approximately 68.1%, and the rest market share was captured by the products of Chongqing Succeway Pharmaceutical Co., Ltd. It is estimated that Pfizer's Lyrica will continue to dominate the Chinese market from 2020 to 2024 but its market share will decline because the price of pregabalin produced by local Chinese companies is lower.

Topics Covered:

  • Development environment of Chinese Pregabalin market 2015-2020
  • Governmental approval of Pregabalin in China
  • Sale value and volume of Pregabalin in China
  • Prices of Pregabalin in China by regions 2019-2020
  • Prices of Pregabalin in China by manufacturers 2019-2020
  • Major Pregabalin manufacturers and their market shares in China
  • Factors influencing the development of the Chinese Pregabalin market
  • Prospects of Chinese Pregabalin market 2020-2024

Key Topics Covered:

1 Relevant Concept of Pregabalin

1.1 Indication

1.2 Development Process of Pregabalin in China

1.3 Governmental Approval of Pregabalin in China

1.4 Sales Value over the World

2 Market Overview of Pregabalin in China, 2013-2018

2.1 Investigation on Sales Value of Pregabalin in China

2.1.1 Total Sales Value

2.1.2 Sales Value by Region

2.2 Investigation on Sales Volume of Pregabalin in China

2.2.1 Total Sales Volume

2.2.2 Sales Volume by Region

2.3 Investigation on Market Size of Pregabalin by Dosage Form in China, 2013-2018

3 Investigation on Market Share of Major Pregabalin Manufacturers in China, 2013-2018

3.1 Major Manufacturers of Pregabalin

3.1.1 Investigation on Market Share by sale value

3.1.2 Investigation on Market Share by sale volume

3.2 Pfizer

3.2.1 Enterprise Profile

3.2.2 Sales Value and Volume of Pregabalin Produced by Pfizer in China

3.3 Chongqing Succeway Pharmaceutical Co., Ltd.

4 Sales Price of Pregabalin in China Market, 2019

4.1 Referential Price of Pregabalin in China Hospital Market

4.1.1 Average Price in China

4.1.2 Sales Price of Pregabalin by Region

4.2 Referential Price of Pregabalin in China by Manufacturers

4.2.1 Pfizer (Lyrica)

4.2.2 Chongqing Succeway Pharmaceutical Co., Ltd. (Lairuike)

5 Prospects of Pregabalin Market, 2020-2024

5.1 Factors influencing Pregabalin Market

5.1.1 Driving Forces and Market Opportunities

5.1.2 Threats and Challenges

5.2 Generic Drugs

5.3 Forecast on Market Size of Pregabalin in China, 2020-2024

5.4 Forecast on Competition Pattern of Pregabalin in China

For more information about this report visit

Laura Wood, Senior Press Manager
[email protected]

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900


Category: BusinessWire, PRAsia

Print This Post

Comments are closed.